相关实验视频

Updated: Jun 17, 2025

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

肠道微生物干预影响抗脂综合征患者的生物化学疾病活动

Valérie L B I Jansen^1,2,3, Dagmar J M van Mourik^2,4,5, Mark Davids⁴

¹Department of Vascular Medicine, Amsterdam UMC Location AMC, University of Amsterdam, Amsterdam, The Netherlands.

TH open : companion journal to thrombosis and haemostasis

|August 6, 2024

概括

肠道微生物群影响抗脂综合征 (APS) 疾病活动. 范科米辛治疗改变了APS患者的生化标志物,特别是那些具有抗脂抗体 (APLA) 的患者.

科学领域:

自免疫性研究的研究.
微生物组研究研究.
临床免疫学临床免疫学

背景情况:

在抗脂综合征 (APS) 中自身抗体的起源仍然不清楚.
肠道微生物组与自身免疫有关,与APS自身抗原的同类可能影响疾病.
动物研究表明,万科米辛改变肠道微生物群会降低疾病活动,但缺乏人类数据.

研究的目的:

调查肠道微生物组改变对人类APS患者疾病活性的影响.
评估万科米辛治疗是否会影响APS的临床表型相关生物标志物.

主要方法:

一项介入前后的研究,涉及15名APS患者,病情稳定,没有胃肠道问题.
患者接受了口服万科米辛 (每天四次500毫克,持续7天),以修改肠道微生物群.
使用生物标志物测量疾病活性,包括抗脂抗体 (APLA),补充剂,炎症和静血参数.

主要成果:

在服用万科米辛7天后 (p=0.03),观察到主要生物标志物复合结果的显著差异,但在第42天没有.
抗脂抗体 (APLA) 标位不受治疗的影响.
后期分析显示,在基线APLA阳性患者中,延长效果,在APLA阴性患者中没有影响.

结论:

肠道微生物组明显影响抗脂综合征 (APS) 患者的生化疾病活动.
这种影响背后的具体机制目前尚不清楚,但似乎是特定于APS.
这些发现表明肠道微生物群和APS病原体之间存在潜在联系.

关键词:

抗脂综合征是一种抗脂综合征.自身免疫性疾病是一种自身免疫性疾病.我们的肠道微生物组.我们的肠道微生物群体

更多相关视频

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment

Published on: November 17, 2018

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...